Outcomes with third-party virus-specific T cells after the use of single-antigen cell lines to predict HLA restriction.

ABSTRACT:

Abstract

Patients with significant T-cell dysfunction from chemotherapy or hematopoietic stem cell transplant are at significant risk for complications of viral infections. Off-the-shelf third-party virus-specific T cells (TP VSTs) are an effective and well-tolerated treatment for the management of infection with adenovirus, BK polyomavirus, cytomegalovirus, and Epstein-Barr virus. TP VST product selection for any particular patient incorporates maximizing the number of HLA matches between the product and the patient, along with consideration of the antiviral activity of the product. We have previously shown that single-antigen cell lines (SALs), cell lines expressing a single HLA molecule, can be used in a flow cytometric-based assay to determine sites of HLA restriction for TP VS

SUBMITTER: Rubinstein JD 

PROVIDER: S-EPMC12744286 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature